Varubi approved for nausea and vomiting associated with cancer chemo
the ONA take:
Rolapitant (Varubi) has been approved by the U.S. Food and Drug Administration (FDA) for the prevention of highly emetogenic and moderately emetogenic chemotherapy-induced nausea and vomiting occurring in the delayed phase, according to a press release by Tesaro, Inc.
Rolapitant should be administered at a dose of 180 mg approximately 1 to 2 hours prior to chemotherapy administration in combination with a 5HT3 receptor antagonist, such as granisetron, and dexamethasone.
"While important strides in preventing nausea and vomiting associated with chemotherapy have been made, still up to half of patients receiving emetogenic cancer chemotherapy can experience delayed CINV," said Richard J. Gralla, M.D., Professor of Medicine at Albert Einstein College of Medicine in New York. "Because NK-1 receptors are key drivers of CINV, especially in the delayed Phase, NK-1 receptor antagonists such as Varubi, when combined with a 5-HT3 receptor antagonist and a corticosteroid, provide enhanced protection from CINV, and do so in the delayed timeframe where the most help is needed."
Adverse events occurring in 3% or more of patients include decreased appetite, neutropenia, dizziness, dyspepsia, urinary tract infection, stomatitis, and anemia.
Rolapitant is an NK-1 receptor antagonist similar to aprepitant (Emend), which is also indicated for the prevention of chemotherapy-induced nausea and vomiting.
The FDA for the prevention of highly emetogenic and moderately emetogenic chemotherapy-induced nausea and vomiting.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Exercise May Mitigate Doxorubicin-related Cardiotoxicity
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
- Exercise May Mitigate Cardiotoxicity Associated With Doxorubicin Treatment
- Mobile Health Apps Becoming More Popular Among Patients and Clinicians
- Online Learning Modules Improve Exercise Counseling, But Not Participation
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|